Skip to Main Content

Author Details

David L Veenstra
University of Washington
1992
250
50
PMIDPaper TitleJournal TitlePublished Year
34766510Exploring Providers' Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs.J Pharm Pract2023
38058141Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.J Manag Care Spec Pharm2023
37644850Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study.Cancer Med2023
37155986Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.Ann Intern Med2023
37470892Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system.Breast Cancer Res Treat2023
37075565Quantifying the value of older adult-specific clinical trials: Post-lumpectomy irradiation among older adults with early-stage breast cancer.J Geriatr Oncol2023
36748709Practical considerations for reinterpretation of individual genetic variants.Genet Med2023
36621880Returning integrated genomic risk and clinical recommendations: The eMERGE study.Genet Med2023
36437194Can we predict trial failure among older adult-specific clinical trials using trial-level factors?J Geriatr Oncol2023
36434257Key drivers of family-level utility of pediatric genomic sequencing: a qualitative analysis to support preference research.Eur J Hum Genet2023
36868347How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancer.Contemp Clin Trials2023
34747265A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.Med Decis Making2022
35679147Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.Cancer2022
35471073Health care utilization and expenditures of parents of children with and without hemophilia A.J Manag Care Spec Pharm2022
35833928Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods.Genet Med2022
35365779Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.Pharmacogenomics J2022
35527331Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.Pharmacoeconomics2022
35752783Prescribing Alzheimer's Disease treatments by provider type and geographic region: a comparison among physicians, nurse practitioners, and physician assistants.BMC Geriatr2022
35752536A Pragmatic Guide to Assessing Real Option Value for Medical Technologies.Value Health2022
35862023Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction.Circ Genom Precis Med2022
35961838Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.J Clin Lipidol2022
36220724Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.Clin Breast Cancer2022
35227606Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.Genet Med2022
35227457Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.Value Health2022
35227445A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning-Based Risk Prediction Models.Value Health2022
35227443Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities.Value Health2022
32905743Genetic Variant Reinterpretation: Economic and Population Health Management Challenges.Popul Health Manag2021
33674997Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".Pharmacoeconomics2021
33591484The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer.Cancer Causes Control2021
33586513Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.J Manag Care Spec Pharm2021
33603322Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study.Clin Ophthalmol2021
34668674Reimbursement for genetic variant reinterpretation: five questions payers should ask.Am J Manag Care2021
34431715Real-world evidence for option value in metastatic melanoma.J Manag Care Spec Pharm2021
34838272Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data.Value Health2021
34687653Conceptualization of utility in translational clinical genomics research.Am J Hum Genet2021
33377442Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.J Manag Care Spec Pharm2021
33377439Use of real-world evidence in economic assessments of pharmaceuticals in the United States.J Manag Care Spec Pharm2021
33455827What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?Patient Educ Couns2021
33367670Artificial intelligence in breast cancer screening: primary care provider preferences.J Am Med Inform Assoc2021
32579152Relationship between genetic knowledge and familial communication of CRC risk and intent to communicate CRCP genetic information: insights from FamilyTalk eMERGE III.Transl Behav Med2021
31631254Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.Pharmacoeconomics2020
31952678Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis.Value Health2020
31706950Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.Res Social Adm Pharm2020
32004415A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes.Clin Transl Sci2020
33251999The use of real-world evidence in ICER's scoping process and clinical evidence assessments.J Manag Care Spec Pharm2020
33119106Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.JAMA Netw Open2020
32804043Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment.Per Med2020
32715412Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome.Pharmacoeconomics2020
32601385Economic value of exome sequencing for suspected monogenic disorders.Genet Med2020
32364664Medication persistence of targeted immunomodulators for plaque psoriasis: A retrospective analysis using a U.S. claims database.Pharmacoepidemiol Drug Saf2020
  • 1 - 50 of 250

Recommended Authors

Orestis A Panagiotou
Department of Health Services, Brown University School of Public Health
Career Start Year 2010
Number of shared co-authors 1
Dalia Dawoud
Stanford University
Career Start Year 2010
Number of shared co-authors 1
Jeff Round
Institute of Health Economics, University of Alberta
Career Start Year 2010
Number of shared co-authors 1
Mike Paulden
School of Public Health, University of Alberta
Career Start Year 2009
Number of shared co-authors 0
Benjamin P Geisler
Massachusetts General Hospital, Harvard Medical School
Career Start Year 2008
Number of shared co-authors 1
James Buchanan
Health Economics Research Centre, University of Oxford
Career Start Year 2007
Number of shared co-authors 2
Christine Y Lu
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Career Start Year 2004
Number of shared co-authors 10
June M McKoy
Feinberg School of Medicine, Northwestern University
Career Start Year 2003
Number of shared co-authors 2
Nicholas Mitsakakis
Institute of Health Policy Management and Evaluation, University of Toronto
Career Start Year 2003
Number of shared co-authors 0
Nilay D Shah
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 1
Sarah Wordsworth
Health Economics Research Centre, University of Oxford
Career Start Year 1997
Number of shared co-authors 3
Christopher McCabe
Queens University Belfast
Career Start Year 1996
Number of shared co-authors 2
Sebastian Schneeweiss
Division of Pharmacoepidemiology, Brigham & Women's Hospital, Harvard Medical School
Career Start Year 1996
Number of shared co-authors 6
George Tomlinson
University Health Network
Career Start Year 1994
Number of shared co-authors 1
Ben van Hout
University of Sheffield
Career Start Year 1993
Number of shared co-authors 1
Dana P Goldman
University of Southern California
Career Start Year 1992
Number of shared co-authors 2
Jason N Doctor
University of Southern California
Career Start Year 1992
Number of shared co-authors 1
Chris L Pashos
Data Sciences Institute, Takeda Pharmaceuticals International Inc.
Career Start Year 1990
Number of shared co-authors 0
Anna N A Tosteson
Dartmouth Cancer Center
Career Start Year 1988
Number of shared co-authors 2
Robert S Epstein
Epstein Health LLC
Career Start Year 1988
Number of shared co-authors 15
Mark S Roberts
School of Public Health, University of Pittsburgh
Career Start Year 1988
Number of shared co-authors 1
Jesse A Berlin
Rutgers University School of Public Health
Career Start Year 1988
Number of shared co-authors 2
Joel Tsevat
Dell Medical School, University of Texas at Austin
Career Start Year 1987
Number of shared co-authors 1
Charles L Bennett
University of South Carolina
Career Start Year 1986
Number of shared co-authors 4
John B Wong
Tufts University School of Medicine
Career Start Year 1986
Number of shared co-authors 0
Frank A Sonnenberg
Robert Wood Johnson Medical School, The State University of New Jersey
Career Start Year 1986
Number of shared co-authors 1
Theodore G Ganiats
university of california san diego
Career Start Year 1983
Number of shared co-authors 5
Elizabeth A Chrischilles
University of Iowa, School of Public Health
Career Start Year 1982
Number of shared co-authors 4
Stan N Finkelstein
University of Toronto
Career Start Year 1977
Number of shared co-authors 0
Dennis W Raisch
The University of New Mexico
Career Start Year 1977
Number of shared co-authors 2

Collaborators

Gail P Jarvik
University of Washington Medical Center
Co-authored papers 22
Wylie Burke
The Heart Institute, Cincinnati Children's Hospital Medical Center
Co-authored papers 18
Emily Beth Devine
University of Washington
Co-authored papers 15
Stephanie M Fullerton
University of Washington School of Medicine
Co-authored papers 12
Marc S Williams
University of Washington Medical Center
Co-authored papers 10
Laura M Amendola
Illumina Inc.
Co-authored papers 10
Josh F Peterson
Vanderbilt University Medical Center
Co-authored papers 9
Katrina A B Goddard
Center for Health Research, Kaiser Permanente Northwest
Co-authored papers 9
Brian H Shirts
Institute for Public Health Genetics, University of Washington
Co-authored papers 9
Nathaniel Hendrix
Harvard T.H. Chan School of Public Health
Co-authored papers 8
Mark J Rieder
Co-authored papers 7
Peter Tarczy-Hornoch
University of Washington School of Medicine, University of Washington
Co-authored papers 7
Amy L McGuire
Baylor College of Medicine.
Co-authored papers 7
Benjamin S Wilfond
University of Washington School of Medicine.
Co-authored papers 7
Patricia A Deverka
Deverka Consulting LLC
Co-authored papers 6
Wendy K Chung
Boston Children's Hospital, Harvard Medical School
Co-authored papers 6
Susan Brown Trinidad
University of Washington
Co-authored papers 5
Donald L Patrick
School of Public Health, 4University of Washington
Co-authored papers 5
Carlos J Gallego
University of Washington
Co-authored papers 5
Lucia A Hindorff
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 5
Kathleen F Mittendorf
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Co-authored papers 5
Paul S Appelbaum
Center for Law, Columbia University Irving Medical Center
Co-authored papers 5
Gregory M Cooper
HudsonAlpha Institute for Biotechnology
Co-authored papers 5
Sean Tunis
Center for Evaluation of Value and Risk in Health, Tufts Medical Center
Co-authored papers 5
Fuki M Hisama
University of Washington
Co-authored papers 5
Deborah A Nickerson
University of Washington
Co-authored papers 5
Peter A Kollman
Co-authored papers 5
Patrick J Heagerty
University of Washington
Co-authored papers 5
E Clayton
Harvard Medical School, Vanderbilt University, Yale University Yale Law School
Co-authored papers 4
Kathleen A Leppig
Kaiser Permanente Washington
Co-authored papers 4
Release 1.2